Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
183.98
+1.42 (+0.78%)
Streaming Delayed Price
Updated: 11:52 AM EDT, Sep 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
↗
Today 11:02 EDT
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program...
Via
MarketBeat
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?
↗
September 22, 2026
The company is looking to prove it can achieve significant success outside the coronavirus market.
Via
The Motley Fool
Is Moderna Stock a Buy After Its Melanoma Breakthrough?
↗
September 22, 2026
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits.
Via
The Motley Fool
Discover which S&P500 stocks are making waves on Tuesday.
↗
September 22, 2026
Via
Chartmill
These S&P500 stocks are moving in today's session
↗
September 22, 2026
Via
Chartmill
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
↗
September 22, 2026
Following last month's super rally, a growing number of analysts are now calling for caution.
Via
The Motley Fool
Discover the top S&P500 movers in Tuesday's pre-market session.
↗
September 22, 2026
Via
Chartmill
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade
↗
September 22, 2026
Via
Chartmill
Topics
Artificial Intelligence
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
↗
September 22, 2026
Investors buying this biotech stock now will get its pipeline essentially for free.
Via
The Motley Fool
Monday's session: top gainers and losers in the S&P500 index
↗
September 21, 2026
Via
Chartmill
Moderna (MRNA) Stock Trades Up, Here Is Why
September 21, 2026
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ...
Via
StockStory
Topics
Artificial Intelligence
Discover which S&P500 stocks are making waves on Monday.
↗
September 21, 2026
Via
Chartmill
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 18, 2026
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases...
Via
The Motley Fool
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
↗
September 18, 2026
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
Via
The Motley Fool
What's going on in today's session: S&P500 movers
↗
September 17, 2026
Via
Chartmill
Why Are Moderna (MRNA) Shares Soaring Today
September 17, 2026
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley G...
Via
StockStory
Topics
Artificial Intelligence
Which S&P500 stocks are moving on Thursday?
↗
September 17, 2026
Via
Chartmill
Thursday's pre-market session: top gainers and losers in the S&P500 index
↗
September 17, 2026
Via
Chartmill
Unpopular Stocks Walking a Fine Line
September 15, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via
StockStory
Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?
↗
September 14, 2026
The biotech is entering a new era.
Via
The Motley Fool
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
↗
September 14, 2026
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma...
Via
MarketBeat
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
↗
September 14, 2026
Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.
Via
MarketBeat
Topics
Artificial Intelligence
Intellectual Property
Stocks
3 Cash-Burning Stocks We Approach with Caution
September 14, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via
StockStory
Top S&P500 movers in Friday's session
↗
September 11, 2026
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Friday.
↗
September 11, 2026
Via
Chartmill
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
September 11, 2026
What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity ma...
Via
StockStory
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 10, 2026
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Via
The Motley Fool
Behind the Most Exciting Stock Pop in Years
↗
September 08, 2026
Moderna's stock is up over 100%.
Via
The Motley Fool
Topics
Artificial Intelligence
Initial Public Offering
World Trade
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
↗
September 06, 2026
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Via
MarketBeat
Topics
Artificial Intelligence
Bonds
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
↗
September 06, 2026
Moderna shares have soared, sunk, and soared again. You might want to consider them.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today